⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
CELC News
Celcuity Inc. Common Stock
Celcuity Presents Updated Results from the PIK3CA MT Cohort of the Phase 3 VIKTORIA-1 Study in Patients with HR+/HER2- Advanced Breast Cancer at the ESMO Congress 2026
globenewswire.com
CELC
Celcuity Presents Updated Data from a Phase 1b/2 Study Evaluating Gedatolisib Plus Darolutamide in Men with Metastatic Castration-Resistant Prostate Cancer at the ESMO Congress 2026
globenewswire.com
CELC
Metastatic HR+/HER2- Breast Cancer - Market Insights, Epidemiology, Competitive Landscape, and Market Forecast - 2036 | 8% CAGR Fueled by Oral SERDs, ADCs, and Targeted Therapies
globenewswire.com
PFE
LLY
AZN
GILD
MRK
ARVN
OMER
CELC
BNTX
Acute Myocardial Infarction (AMI) - Market Insights, Epidemiology, and Market Forecast Now Available; Acute Myocardial Infarction (AMI) Market Projected to Reach Approximately USD 6.00 Billion by 2036
globenewswire.com
AMGN
MRK
REGN
AZN
PFE
BMY
JNJ
VTRS
CELC
NVO
ARWR
Celcuity Announces Multiple Presentations At The European Society For Medical Oncology (ESMO) Congress 2026
globenewswire.com
CELC
Form 8-K
sec.gov
CELC
Celcuity Appoints David Gryska To Its Board Of Directors
globenewswire.com
CELC
Form 8-K
sec.gov
CELC
Celcuity Announces That REVTORPYK™ (gedatolisib) Is Now Commercially Available In The United States
globenewswire.com
CELC
CAR T-Cell Therapy for Non-Hodgkin’s Lymphoma Market Set for Expansion Through 2036, Fueled by Treatment Innovation and Rising Patient Demand
globenewswire.com
GILD
NVS
BMY
CRSP
BIO
ADBT
BIIB
JNJ
REGN
AMGN
CELC
ALLO
MBIO
AUTL